| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Pediatrics,
Microbiology/Immunology and Pathology, Dalhousie University, and
Institute for Marine Biosciences, National Research Council, Halifax, Nova Scotia, Canada
During inflammation, T lymphocytes migrate out of the blood across the vascular endothelium in a multistep process. The receptors mediating T cell adhesion to endothelium are well characterized; however, the molecules involved in T cell transendothelial migration (TEM) subsequent to lymphocyte adhesion to the endothelium are less clear. To identify receptors mediating TEM, mAbs were produced against human blood T cells adhering to IFN-
-activated HUVEC in mice and tested for inhibition of lymphocyte TEM across cytokine-activated HUVEC. Most of the mAbs were against 
1 and 2 integrins, but one mAb, 6B9, significantly inhibited T cell TEM across IFN-, TNF-
, and IFN- plus TNF--stimulated HUVEC, and did not react with an integrin. 6B9 mAb did not inhibit T cell adhesion to HUVEC, suggesting that 6B9 blocked a novel pathway in T cell TEM. The 6B9 Ag was 80 kDa on SDS-PAGE, and was expressed by both blood leukocytes and HUVEC. Immunoaffinity purification and mass spectrometry identified this Ag as tissue transglutaminase (tTG), a molecule not known to mediate T cell TEM. Treatment of HUVEC with 6B9 was more effective than treatment of T cells. 6B9 blockade selectively inhibited CD4-, but not CD4+, T cell TEM, suggesting a role for tTG in recruitment of CD8+ T lymphocytes. Thus, 6B9 is a new blocking mAb to human tTG, which demonstrates that tTG may have a novel role in mediating CD8+ T cell migration across cytokine-activated endothelium and infiltration of tissues during inflammation.
This article has been cited by other articles:
|
|
 |
|
  A. Verma, S. Guha, P. Diagaradjane, A. B. Kunnumakkara, A. M. Sanguino, G. Lopez-Berestein, A. K. Sood, B. B. Aggarwal, S. Krishnan, J. G. Gelovani, et al. Therapeutic Significance of Elevated Tissue Transglutaminase Expression in Pancreatic Cancer Clin. Cancer Res., April 15, 2008; 14(8): 2476 - 2483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Byrne, F. Ryan, J. Jackson, C. Feighery, and J. Kelly Mutagenesis of the catalytic triad of tissue transglutaminase abrogates coeliac disease serum IgA autoantibody binding Gut, March 1, 2007; 56(3): 336 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Verma, H. Wang, B. Manavathi, J. Y. Fok, A. P. Mann, R. Kumar, and K. Mehta Increased Expression of Tissue Transglutaminase in Pancreatic Ductal Adenocarcinoma and Its Implications in Drug Resistance and Metastasis Cancer Res., November 1, 2006; 66(21): 10525 - 10533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Balajthy, K. Csomos, G. Vamosi, A. Szanto, M. Lanotte, and L. Fesus Tissue-transglutaminase contributes to neutrophil granulocyte differentiation and functions Blood, September 15, 2006; 108(6): 2045 - 2054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kabir-Salmani, S. Shiokawa, Y. Akimoto, K. Sakai, K. Sakai, and M. Iwashita Tissue Transglutaminase at Embryo-Maternal Interface J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4694 - 4702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Mehta, J. Fok, F. R. Miller, D. Koul, and A. A. Sahin Prognostic Significance of Tissue Transglutaminase in Drug Resistant and Metastatic Breast Cancer Clin. Cancer Res., December 1, 2004; 10(23): 8068 - 8076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sotnikov, R. Hershkoviz, V. Grabovsky, N. Ilan, L. Cahalon, I. Vlodavsky, R. Alon, and O. Lider Enzymatically Quiescent Heparanase Augments T Cell Interactions with VCAM-1 and Extracellular Matrix Components under Versatile Dynamic Contexts J. Immunol., May 1, 2004; 172(9): 5185 - 5193. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
